Search

Search Constraints

You searched for: Author/Creator Ramanujam, Meera

Search Results

1. 32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers. (April 2019)

2. A Novel Tetrapeptide Derivative Exhibits In Vitro Inhibition of Neutrophil-Derived Reactive Oxygen Species and Lysosomal Enzymes Release. (30th May 2013)

3. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Issue 6 (22nd June 2019)

4. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study. Issue 6 (22nd March 2019)

5. II-06 Therapeutic blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of bruton's tyrosine kinase. (31st August 2016)

6. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. Issue 4 (20th November 2020)

7. Suppression of Glomerulonephritis in Lupus‐Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase. Issue 9 (26th August 2013)

8. Suppression of Glomerulonephritis in Lupus‐Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase. Issue 9 (26th August 2013)